1. Introduction {#sec1-ijms-19-00900}
===============

Breast cancer (BC) is one of the most common cancers in women worldwide \[[@B1-ijms-19-00900],[@B2-ijms-19-00900]\]. The early detection of breast cancer plays an important role in successful treatment and outcome. To date, mammography is still the main screening method for breast cancer early detection. However, the limitations of this method are noticed as tumors can only be partially identified in women (mostly young women) with dense breasts \[[@B3-ijms-19-00900],[@B4-ijms-19-00900]\]. Therefore, the identification of new reliable biomarkers for the screening and diagnosis of breast cancer is urgently needed.

Epigenetic events are critical factors in the development of human cancers \[[@B5-ijms-19-00900],[@B6-ijms-19-00900],[@B7-ijms-19-00900],[@B8-ijms-19-00900]\]. Aberrant methylation in the promoter regions of tumor suppressor genes is related to carcinogenesis through transcriptional silencing of gene expression \[[@B9-ijms-19-00900]\], leading to the initiation and progression of cancer \[[@B10-ijms-19-00900],[@B11-ijms-19-00900]\]. Global hypomethylation and gene-specific hypermethylation were shown to be associated with malignancy \[[@B12-ijms-19-00900],[@B13-ijms-19-00900],[@B14-ijms-19-00900]\]. Several studies showed that these epigenetic changes were early events of a variety of cancers including breast \[[@B15-ijms-19-00900],[@B16-ijms-19-00900],[@B17-ijms-19-00900]\], lung \[[@B18-ijms-19-00900]\], and colon cancer \[[@B19-ijms-19-00900]\], and all of them could be recognized as common hallmarks in different kinds of tumors \[[@B20-ijms-19-00900]\]. Similar alterations also existed in blood-derived DNA, suggesting that blood-based DNA methylation could reveal new biomarkers for BC screening or diagnosis \[[@B21-ijms-19-00900],[@B22-ijms-19-00900]\]. A major advantage of blood-based DNA methylation is the easy accessibility of blood samples to investigate DNA methylation in cancer patients.

Recently, studies have been focused on two tumor suppressor genes, RAS-association domain family member 1A (*RASSF1A*) and ataxia-telangiectasia mutated gene (*ATM*). *RASSF1A* takes part in apoptosis induction, proliferation regulation, and microtubules stabilization \[[@B23-ijms-19-00900]\]. Aberrant hypermethylation of *RASSF1A* has been demonstrated in various solid tumors, including lung, prostate, ovary, and breast cancer tissue samples \[[@B24-ijms-19-00900],[@B25-ijms-19-00900],[@B26-ijms-19-00900],[@B27-ijms-19-00900]\]. Furthermore, a previous study has demonstrated no *RASSF1A* promoter hypermethylation in peripheral blood from normal blood donors, which suggested the potential of *RASSF1A* as a biomarker for cancers \[[@B28-ijms-19-00900]\]. *ATM* plays a critical role in repairing DNA double-strand breaks and is involved in numerous processes including recognition of damaged DNA, recruitment of repair proteins, signaling to cell cycle checkpoints, transcriptional regulation, and activation of apoptosis \[[@B29-ijms-19-00900]\]. Hypermethylation of the *ATM* promoter has been shown in gastric lymphoma, glioma, colonic cancer, adenoma, and breast cancer tissue samples \[[@B30-ijms-19-00900],[@B31-ijms-19-00900],[@B32-ijms-19-00900],[@B33-ijms-19-00900]\]. Moreover, we summarized recent studies which investigated promoter methylation changes of *RASSF1A* and *ATM* in peripheral blood (plasma, serum, or whole blood) from BC patients and healthy controls (see [Supplementary Table S1](#app1-ijms-19-00900){ref-type="app"}). To our surprise, the results of these studies were inconsistent. The promoter methylation of *RASSF1A* did not show a significant difference between BC patients and healthy controls in two quantitative studies \[[@B34-ijms-19-00900],[@B35-ijms-19-00900]\]. It is worth noting that the sample sizes analyzed in these two studies were rather low. For *ATM*, two studies reported its hypermethylation in BC patients, but the CpG sites they investigated were located in the gene body or intragenic region instead of the promoter \[[@B36-ijms-19-00900],[@B37-ijms-19-00900]\]. Altogether, blood-based DNA methylation of the *RASSF1A* and *ATM* promoter remains unclear in BC patients. However, these findings reveal the potential of *RASSF1A* and *ATM* promoter hypermethylation as novel biomarkers for cancer early detection.

Therefore, in this study, we aimed to conduct a case-control study with a large sample size to investigate *RASSF1A* and *ATM* promoter methylation in BC patients and healthy controls. A quantitative method, the MassARRAY EpiTYPER assay, was applied by using peripheral blood DNA in order to find useful blood-based biomarkers for BC early detection.

In addition, we compared previously published results of blood-based DNA methylation of specific genes found to be associated with breast cancer with our results by Infinium HumanMethylation450 BeadChip (450K) array analysis of sporadic breast cancer cases and healthy controls.

2. Results {#sec2-ijms-19-00900}
==========

2.1. Promoter Methylation Levels of RASSF1A and ATM in BC Patients and Healthy Controls and Its Correlation to Clinical Characteristics {#sec2dot1-ijms-19-00900}
---------------------------------------------------------------------------------------------------------------------------------------

In order to investigate the promoter methylation levels of *RASSF1A* and *ATM*, we performed the MassARRAY EpiTYPER assay by using peripheral blood DNA from BC patients and healthy controls. Our results showed that the promoter methylation levels of *RASSF1A* and *ATM* were quite low in both BC patients and healthy controls. In the amplicon of *RASSF1A*, 17 CpG sites were measured and the average methylation levels of all these CpG sites were 0.037 and 0.042 in the BC patients and the healthy controls, respectively. Compared to the healthy controls, no significant difference was represented in the methylation levels of the BC patients among all these 17 CpG sites (see [Table 1](#ijms-19-00900-t001){ref-type="table"}).

As for *ATM*, 30 CpG sites were analyzed in its amplicon. The average methylation levels of all investigated CpG sites of *ATM* were 0.047 and 0.048 in the BC patients and the healthy controls, respectively. No visible difference was detected in the methylation levels of these CpG sites between the BC cases and the healthy controls (see [Table 2](#ijms-19-00900-t002){ref-type="table"}). The CpG sites of *RASSF1A* and *ATM* analyzed in this study are shown in [Supplementary Figure S1](#app1-ijms-19-00900){ref-type="app"}.

To further explore the association between the promoter methylation of *RASSF1A*/*ATM* and the clinical characteristics of the BC patients, statistical analyses were performed. All the BC patients were classified into different subgroups according to their clinical properties (see [Table 3](#ijms-19-00900-t003){ref-type="table"}). To our surprise, no significant correlation was represented between the methylation levels of all the CpG sites in *RASSF1A* or *ATM* amplicons and the clinical characteristics of the BC patients (see [Supplementary Tables S2 and S3](#app1-ijms-19-00900){ref-type="app"}).

Taken together, these results demonstrated that the promoter methylation levels of *RASSF1A* and *ATM* included in our study were not statistically different between the BC patients and the healthy controls.

2.2. Comparison of the Results from This Study with the Results of Infinium HumanMethylation450 BeadChip Array and with Literature {#sec2dot2-ijms-19-00900}
----------------------------------------------------------------------------------------------------------------------------------

To better interpret the results of the Sequenom MassARRAY EpiTYPER assay, we also performed an epigenome-wide Infinium HumanMethylation450 BeadChip array (450K array). In line with the MassARRAY data, the methylation levels of all the investigated CpG sites of *RASSF1A* and *ATM* were rather low. No significant difference was revealed in the methylation levels of *RASSF1A* and *ATM* between the BC patients and the healthy controls. Interestingly, we identified four CpG sites of *RASSF1A* and 13 CpG sites of *ATM* which were identical in both the Sequenom MassArray EpiTYPER assay and the 450K array. These data confirmed the findings of our MassARRAY analysis (see [Table 4](#ijms-19-00900-t004){ref-type="table"}).

To understand the current research status on gene-specific DNA methylation in blood-based DNA as a screening biomarker for breast cancer early detection, we reviewed recent studies which investigated blood-based DNA methylation of *BRCA1*, *APC*, *RARB*, *ESR1*, *CDH1*, *SYK*, *TIMP3*, *GSTP1*, *DAPK*, and *IGF2* between BC patients and healthy controls \[[@B38-ijms-19-00900]\]. Interestingly, the results of blood DNA methylation levels of *BRCA1*, *APC*, *RARB*, *ESR1*, *TIMP3*, and *GSTP1* were inconsistent among the previous studies, but a higher frequency of methylated *DAPK* in peripheral DNA was reported in BC cases compared to healthy controls in several studies (see [Supplementary Table S4](#app1-ijms-19-00900){ref-type="app"}) \[[@B36-ijms-19-00900],[@B37-ijms-19-00900],[@B39-ijms-19-00900],[@B40-ijms-19-00900]\]. Moreover, the methylation levels of *CDH1*, *IGF2*, and *SYK* were not significantly different in peripheral blood DNA between BC cases and healthy controls according to the published data \[[@B34-ijms-19-00900],[@B35-ijms-19-00900],[@B41-ijms-19-00900],[@B42-ijms-19-00900],[@B43-ijms-19-00900],[@B44-ijms-19-00900]\].

Next, we investigated the methylation levels of these genes by a 450K array from our own group. Compared to the healthy controls, the methylation levels did not show a significant difference in most of the CpG sites of these genes in the BC cases, except for a few CpG sites including *BRCA1* (cg13782816), *APC* (cg01240931 and cg14511739), *ESR1* (cg25565730), *CDH1* (cg26508465), and *GSTP1* (cg06841499) (see [Supplementary Table S4](#app1-ijms-19-00900){ref-type="app"}).

3. Discussion {#sec3-ijms-19-00900}
=============

In this work, we conducted a large cohort case-control study to investigate the promoter methylation changes of two tumor suppressor genes (*RASSF1A* and *ATM*) in peripheral blood DNA as potential epigenetic markers for breast cancer risk and early detection. To our surprise, no significant differences in the methylation level of *RASSF1A* and *ATM* in peripheral blood DNA were revealed between BC cases and healthy controls.

*RASSF1A* methylation in BC patients has been analyzed by several groups using either blood serum or blood plasma samples \[[@B39-ijms-19-00900],[@B40-ijms-19-00900],[@B45-ijms-19-00900],[@B46-ijms-19-00900],[@B47-ijms-19-00900],[@B48-ijms-19-00900],[@B49-ijms-19-00900],[@B50-ijms-19-00900]\]. Jo-Heon Kim et al. observed significantly higher methylation frequencies of *RASSF1A* in ductal carcinoma in situ (DCIS) or invasive ductal carcinoma (IDC) than in control subjects, but the CpG sites they investigated in the *RASSF1A* promoter region were different from ours \[[@B49-ijms-19-00900]\]. In contrast, Zmetakova et al., evaluated DNA methylation profiles of the *RASSF1A* promoter by pyrosequencing in invasive breast cancer. They demonstrated no significant difference in peripheral blood DNA between BC cases and healthy controls, which was in line with our findings \[[@B35-ijms-19-00900]\]. Moreover, another study by Brooks et al., also showed no significant difference in *RASSF1A* promoter methylation between BC cases and controls, although they used serum instead of whole blood samples. Interestingly, the CpG sites analyzed in their study partially overlapped with some CpG sites in our *RASSF1A* amplicon \[[@B51-ijms-19-00900]\].

For *ATM*, we demonstrated that the promoter methylation level in peripheral blood DNA of BC patients was not significantly different from that of healthy controls. Consistent with this, Flanagan et al. detected no significant difference in methylation of the *ATM* promoter CpG islands in white blood cell DNA between BC cases and healthy controls \[[@B36-ijms-19-00900]\].

In fact, it is difficult to compare the results between our study and the published data, where different techniques for methylation analysis have been used and different CpG sites have been investigated. Moreover, depending on the technique used for quantification, methylation levels can differ, even for the same CpG site \[[@B52-ijms-19-00900]\]. The promoter region is located at around 100--1000 base pairs before the transcription start sites. A length of around 100--500 base pairs can be amplified by PCR, which means that the investigation cannot cover the entire promoter region. Currently, there is no standard for blood DNA methylation analysis. The exact quantity of methylated CpG sites as the biomarker for breast cancer risk remains unclear.

In our study, we chose whole blood DNA to investigate the methylation levels. Recently, the pivotal significance of circulating tumor cells (CTCs) has been realized for breast cancer patients, even in patients without metastases. It is possible that the whole blood was mixed by CTCs, further affecting the analysis of *RASSF1A* or *ATM* promoter methylation. In fact, peripheral blood samples from epidemiological studies always comprise mixed cell populations, but it is not feasible or practical to fractionate cell populations in an epidemiological study setting \[[@B53-ijms-19-00900]\]. At present, many studies use cell-free DNA (cfDNA) to investigate DNA methylation, but its low concentration and small fragments may disrupt the detection of blood-based DNA methylation \[[@B54-ijms-19-00900],[@B55-ijms-19-00900],[@B56-ijms-19-00900]\]. Even if the pooling method can improve the concentration of cfDNA, the possible bias may still occur. In addition, the origin of cfDNA is still uncertain and it requires more evidence to elucidate the mechanism of cfDNA release \[[@B57-ijms-19-00900]\].

Radpour et al. demonstrated that heterogeneity of methylation changes exists in carcinogenesis, but no single gene has been shown to be methylated in all types of breast cancer \[[@B58-ijms-19-00900]\]. Therefore, a panel of genes should be considered as biomarkers for breast cancer screening. Our 450K data analyzed additional ten genes to screen for potential methylation CpG sites as biomarkers for breast cancer early detection. The methylation levels did not show a significant difference in most of the CpG sites of these genes in BC cases.

With the analysis of *RASSF1A* and *ATM* using the MassARRAY EpiTYPER assay, we could confirm the results of our 450K methylation data for these two genes. However, the methylation levels detected in our samples were quite low. We identified that the average methylation levels of *RASSF1A* and *ATM* were at around 0.04 and 0.05, respectively. In accordance with this, a study by Cho et al., reported that the methylation level of *RASSF1A* was below 4% \[[@B34-ijms-19-00900]\]. The MassARRAY system could detect the methylation level as low as 5% \[[@B59-ijms-19-00900]\]. For some of the analyzed CpG sites, no detectable quantitative value could be gained because the results were below this detection limit. Future studies applying digital PCR techniques in next-generation sequencing (PCR/NGS)-based analysis may improve the detection limit.

Another limitation of the 450K results was the limited sample size, which included only 48 cases and 48 controls. Thus, larger multicenter prospective study cohorts are needed to validate these results.

In conclusion, the promoter CpG methylation status of *RASSF1A* and *ATM* in peripheral blood included in our study was unable to distinguish between BC cases and healthy controls. Further prospective studies should be carried out to evaluate whether *RASSF1A* or *ATM* promoter methylation could be suitable biomarkers for breast cancer early detection \[[@B39-ijms-19-00900]\].

4. Materials and Methods {#sec4-ijms-19-00900}
========================

4.1. Study Population {#sec4dot1-ijms-19-00900}
---------------------

This study was approved by the Ethics Committee of University Hospital in Heidelberg (S-039/2008, 27 April 2009; S-175/2010, 26 May 2010). All samples of the BC cases and the healthy controls were obtained from centers in southwest Germany. All the enrolled patients and the healthy controls were Caucasian and were given written informed consent. Peripheral whole-blood samples from the BC patients were successively collected before therapeutic treatments at the University Hospital of Heidelberg. Clinical characteristics of the BC patients were defined according to the American Joint Committee on Cancer staging manual \[[@B60-ijms-19-00900]\]. Detailed characteristics of the sporadic BC cases were described in [Table 3](#ijms-19-00900-t003){ref-type="table"}. In the group of healthy controls, peripheral whole-blood samples were consecutively collected from blood donors at the University Hospital of Heidelberg. Donors approved the use of their blood samples for research purposes. All the donors were healthy when donating blood and none of them had a family history of BC. Blood samples were collected between 2011 and 2014 and a total of 229 sporadic BC patients and 151 healthy controls were randomly selected for this study (see [Table 5](#ijms-19-00900-t005){ref-type="table"}).

4.2. DNA Isolation and Bisulfite Conversion {#sec4dot2-ijms-19-00900}
-------------------------------------------

DNA was isolated from 200 µL aliquots of whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. NanoDrop ND-1000 UV/Vis-Spectralphotometer 3.3 (peqLab, Erlangen, Germany) was used to measure DNA quality and quantity. DNA bisulfite treatment was carried out using the EZ-96 DNA methylation Gold kit (Zymo Research Corporation, Orange, CA, USA) as described by the manufacturer.

4.3. Primer Design and PCR Amplification {#sec4dot3-ijms-19-00900}
----------------------------------------

The PCR primers for *RASSF1A* and *ATM* amplicon sequences (see [Table 6](#ijms-19-00900-t006){ref-type="table"} and [Table 7](#ijms-19-00900-t007){ref-type="table"}) were designed with the online tool "epidesigner" (<http://www.epidesigner.com/start3.html>). PCR was performed in a final reaction volume of 6 µL which included bisulfite-treated DNA (10 ng/µL), CoralLoad Buffer (10×; Qiagen, Valencia, CA, USA), forward and reverse primers (1 µM of each; Sigma, Darmstadt, Germany), dNTPs (10 mM), and HotStar Taq DNA polymerase (5 U/µL; Qiagen, Valencia, CA, USA). The touch-down PCR profile was 5 min of activation at 95 °C, 30 s of denaturation at 94 °C, and 30 s of annealing at a temperature reduced from 59 °C to 53 °C (every 2 °C), followed by a final extension at 72 °C for 1 min. After a maintenance of 5 min at 72 °C, the reaction ended up at 4 °C. PCR products were electrophoresed on 1% agarose gels and evaluated under ultraviolet light.

4.4. Methylation Analysis {#sec4dot4-ijms-19-00900}
-------------------------

For methylation analysis, the Sequenom MassARRAY EpiTYPER assay was applied as described previously \[[@B61-ijms-19-00900]\]. The PCR amplicons were conducted subsequently according to the protocol of the Sequenom EpiTYPER Assay and cleaned by Resin. A nanodispenser was used to transfer the products to a 384 SpectroCHIP (SEQUENOM, San Diego, CA, USA). The chips were read by a Sequenom Mass Spectrometer system (SEQUENOM, San Diego, CA, USA). Data was gathered by SpectroACQUIRE v3.3.1.3 software (SEQUENOM, San Diego, CA, USA) and visualized with MassArray EpiTYPER v1.0 software (SEQUENOM, San Diego, CA, USA). Results were depicted as "beta" values (β) between 0 and 1.

4.5. 450K Methylation Study {#sec4dot5-ijms-19-00900}
---------------------------

Epigenome-wide DNA methylation profiling on 96 age matched blood DNAs from 48 sporadic BC cases and 48 healthy controls was performed by applying Infinium HumanMethylation450 BeadChip (450K) as described before \[[@B61-ijms-19-00900]\]. In brief, DNA was extracted from whole blood samples. Then, the DNA samples were bisulfate converted, purified, and applied to the BeadChips (Illumina, San Diego, CA, USA). Image processing and data extraction were performed following Illumina's instructions. Further details of the 450K array analysis were given in Tang et al. \[[@B61-ijms-19-00900]\].

4.6. Statistical Analysis {#sec4dot6-ijms-19-00900}
-------------------------

SPSS statistics 24.0 (IBM, NY, USA) was used for statistical analyses of the data. Normality of distribution was evaluated by the Kolmogorov-Smirnoff test. Non-normally distributed data was analyzed by the nonparametric Mann-Whitney *U* or Kruskal-Wallis *H* test. All tests were performed two-tailed at the significance level *p* \< 0.05.
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breast cancer

RASSF1A

RAS-association domain family member 1A gene

ATM

ataxia-telangiectasia mutated gene

450K

Infinium HumanMethylation450 BeadChip

IQR

interquartile range

DCIS

ductal carcinoma in situ

IDC

invasive ductal carcinoma

cfDNA

cell free DNA

CTCs

circulating tumor cells
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###### 

Comparison of *RASSF1A* DNA methylation between the BC patients and the healthy controls in peripheral blood.

  CpG Site               Case, *n*   Control, *n*   BC Cases Median (IQR)   Controls Median (IQR)   *p*-Value \*   *p*-Value \*\*
  ---------------------- ----------- -------------- ----------------------- ----------------------- -------------- ----------------
  *RASSF1A*\_CpG_1       222         144            0.00 (0.00--0.00)       0.00 (0.00--0.00)       0.03           0.31
  *RASSF1A*\_CpG_8       216         134            0.00 (0.00--0.02)       0.00 (0.00--0.02)       1.00           0.76
  *RASSF1A*\_CpG_9       223         141            0.01 (0.00--0.02)       0.01 (0.00--0.03)       1.00           0.78
  *RASSF1A*\_CpG_11,12   187         121            0.13 (0.11--0.16)       0.14 (0.11--0.17)       1.00           0.38
  *RASSF1A*\_CpG_13      222         141            0.04 (0.00--0.08)       0.04 (0.00--0.08)       1.00           0.90
  *RASSF1A*\_CpG_14,15   187         121            0.13 (0.11--0.16)       0.14 (0.11--0.17)       1.00           0.35
  *RASSF1A*\_CpG_16      226         146            0.02 (0.00--0.03)       0.02 (0.02--0.03)       1.00           0.15
  *RASSF1A*\_CpG_19      216         134            0.00 (0.00--0.02)       0.00 (0.00--0.02)       1.00           0.09
  *RASSF1A*\_CpG_20      216         134            0.00 (0.00--0.02)       0.00 (0.00--0.02)       1.00           0.34
  *RASSF1A*\_CpG_21,22   226         145            0.05 (0.04--0.06)       0.05 (0.03--0.07)       0.62           0.64
  *RASSF1A*\_CpG_23      226         146            0.00 (0.00--0.00)       0.00 (0.00--0.00)       0.28           0.70
  *RASSF1A*\_CpG_24      226         145            0.03 (0.02--0.05)       0.03 (0.02--0.07)       1.00           0.79
  *RASSF1A*\_CpG_25      223         141            0.01 (0.00--0.02)       0.01 (0.00--0.03)       1.00           0.31
  *RASSF1A*\_CpG_26      226         146            0.04 (0.03--0.05)       0.04 (0.03--0.05)       1.00           0.76
  MEAN                   226         146            0.037 (0.029--0.048)    0.042 (0.032--0.054)    0.25           0.78

Abbreviations: IQR: interquartile range. \* *p*-value for the difference between controls and patients was analyzed by Mann-Whitney *U* test and was adjusted by Bonferroni-Holm method, α = 0.00333. \*\* *p*-value for the difference between controls and patients was analyzed by logistic regression and was adjusted by age, α = 0.05.
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###### 

Comparison of *ATM* DNA methylation between the BC patients and the healthy controls in peripheral blood.

  CpG Site             Case, *n*   Control, *n*   BC Cases Median (IQR)   Controls Median (IQR)   *p*-Value \*   *p*-Value \*\*
  -------------------- ----------- -------------- ----------------------- ----------------------- -------------- ----------------
  *ATM*\_CpG_1         222         146            0.02 (0.01--0.03)       0.02 (0.01--0.02)       1.00           0.95
  *ATM*\_CpG_2,3,4,5   142         95             0.07 (0.06--0.10)       0.07 (0.06--0.09)       1.00           0.91
  *ATM*\_CpG_6         223         146            0.00 (0.00--0.00)       0.00 (0.00--0.00)       1.00           0.37
  *ATM*\_CpG_7,8       223         146            0.05 (0.03--0.06)       0.04 (0.03--0.06)       1.00           0.60
  *ATM*\_CpG_10,11     221         145            0.11 (0.10--0.13)       0.12 (0.10--0.13)       1.00           0.95
  *ATM*\_CpG_12        223         146            0.00 (0.00--0.00)       0.00 (0.00--0.00)       1.00           0.94
  *ATM*\_CpG_13,14     223         146            0.03 (0.02--0.04)       0.03 (0.02--0.04)       1.00           0.43
  *ATM*\_CpG_17        219         145            0.00 (0.00--0.04)       0.01 (0.00--0.04)       1.00           0.73
  *ATM*\_CpG_18,19     223         146            0.13 (0.12--0.16)       0.14 (0.12--0.18)       0.22           0.18
  *ATM*\_CpG_20,21     223         146            0.02 (0.02--0.03)       0.02 (0.02--0.03)       1.00           0.36
  *ATM*\_CpG_26        219         146            0.06 (0.04--0.09)       0.07 (0.05--0.09)       1.00           0.21
  *ATM*\_CpG_27        223         146            0.11 (0.10--0.12)       0.11 (0.10--0.12)       1.00           0.66
  *ATM*\_CpG_28        222         146            0.02 (0.02--0.03)       0.02 (0.02--0.03)       1.00           0.75
  *ATM*\_CpG_29        223         146            0.03 (0.02--0.03)       0.03 (0.02--0.03)       1.00           0.68
  *ATM*\_CpG_32        223         145            0.00 (0.00--0.00)       0.00 (0.00--0.00)       1.00           0.53
  *ATM*\_CpG_33        223         146            0.00 (0.00--0.00)       0.00 (0.00--0.00)       1.00           0.15
  *ATM*\_CpG_34        223         146            0.13 (0.10--0.16)       0.14 (0.10--0.18)       1.00           0.70
  *ATM*\_CpG_35        219         145            0.00 (0.00--0.04)       0.01 (0.00--0.04)       1.00           0.78
  *ATM*\_CpG_36        223         145            0.00 (0.00--0.00)       0.00 (0.00--0.00)       1.00           0.14
  *ATM*\_CpG_37        223         146            0.13 (0.10--0.16)       0.14 (0.10--0.18)       1.00           0.16
  *ATM*\_CpG_38        192         135            0.00 (0.00--0.01)       0.00 (0.00--0.01)       1.00           0.95
  *ATM*\_CpG_39        223         146            0.02 (0.01--0.04)       0.02 (0.01--0.03)       1.00           0.91
  MEAN                 223         146            0.047 (0.042--0.055)    0.048 (0.042--0.056)    1.00           0.37

Abbreviations: IQR: interquartile range. \* *p*-value for the difference between controls and patients was analyzed by Mann-Whitney *U* test and was adjusted by Bonferroni-Holm method, α = 0.00227. \*\* *p*-value for the difference between controls and patients was analyzed by logistic regression and was adjusted by age, α = 0.05.
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###### 

Characteristics of the sporadic BC patients.

  Characteristics                                              BC Patients Number (%)
  ------------------------------------------------------------ ------------------------
  Tumor, lymph node and metastasis (TNM) Stage                 
  stage 0                                                      1 (0.4%)
  stage I                                                      69 (30.1%)
  stage II                                                     72 (31.4%)
  stage III                                                    15 (6.6%)
  stage IV                                                     4 (1.7%)
  neoadjuvant chemotherapy \*                                  50 (21.8%)
  unknown                                                      18 (7.9%)
  Type of BC                                                   
  Ductal                                                       179 (78.2%)
  Lobular                                                      13 (5.7%)
  Ductal-Lobular                                               3 (1.3%)
  ductal carcinoma in situ (DCIS)                              4 (1.7%)
  Others                                                       10 (4.4%)
  unknown                                                      24 (10.5%)
  Estrogen receptor (ER) Status ^a^                            
  negative                                                     21 (9.2%)
  positive                                                     160 (69.9%)
  unknown                                                      48 (21.0%)
  Progesterone receptor (PR) Status ^a^                        
  negative                                                     36 (15.7%)
  positive                                                     145 (63.3%)
  unknown                                                      48 (21.0%)
  Human epidermal growth factor receptor 2 (HER2) Status ^b^   
  negative                                                     165 (72.1%)
  positive                                                     16 (7.0%)
  unknown                                                      48 (21.0%)

^a^ Immunoreactive score (IRS): ER/PR negative: IRS 0--2; ER/PR positive: IRS 3--12. ^b^ HER2 negative: IHC-score 0--1; HER2 positive: IHC-score 3; If IHC-score = 2, FISH/CISH was further analyzed, HER2 is recognized as positive if it is amplified. \* Patients were treated with neoadjuvant chemotherapy, no stage is given here.
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###### 

Comparison of methylation levels of peripheral blood DNA between different analytical methods.

  Gene            450K Results   Sequenom MassARRAY EpiTYPER Assay                                                                                                                        
  --------------- -------------- ----------------------------------- --------------- --------------- -------- --------- ---------------------- ---------------------- ------------------- ------
  ***RASSF1A***   cg 12966367    48/48                               0.029 ± 0.005   0.027 ± 0.004   0.19     CpG_1     229/151                0.00 (0.00--0.00)      0.00 (0.00--0.00)   0.03
  cg25486143      48/48          0.014 ± 0.002                       0.014 ± 0.002   0.80            CpG_14   229/151   0.13 (0.11--0.16)      0.14 (0.11--0.17)      1.00                
  cg06172942      48/48          0.038 ± 0.007                       0.038 ± 0.011   0.91            CpG_15   229/151   0.13 (0.11--0.16)      0.14 (0.11--0.17)      1.00                
  cg 03297783     48/48          0.015 ± 0.002                       0.016 ± 0.002   0.35            CpG_19   229/151   0.00 (0.00--0.02)      0.00 (0.00--0.02)      1.00                
  cg08047457 \*   48/48          0.030 ± 0.004                       0.030 ± 0.004   0.87            CpG_2    229/151   ---                    ---                    ---                 
  cg25747192 \*   48/48          0.043 ± 0.007                       0.043 ± 0.008   0.99            CpG_3    229/151   ---                    ---                    ---                 
  cg21554552 \*   48/48          0.031 ± 0.005                       0.030 ± 0.005   0.42            CpG_4    229/151   ---                    ---                    ---                 
  cg27569446 \*   48/48          0.012 ± 0.002                       0.011 ± 0.002   0.65            CpG_5    229/151   ---                    ---                    ---                 
  cg04540383 \*   48/48          0.032 ± 0.004                       0.033 ± 0.005   0.92            CpG_18   229/151   ---                    ---                    ---                 
  Mean            48/48          0.204 ± 0.005                       0.205 ± 0.005   0.56            Mean     229/151   0.037 (0.029--0.048)   0.042 (0.032--0.054)   0.25                
  ***ATM***       cg19288979     48/48                               0.075 ± 0.006   0.076 ± 0.007   0.95     CpG_1     229/151                0.02 (0.01--0.03)      0.02 (0.01--0.02)   1.00
  cg10610482      48/48          0.040 ± 0.005                       0.037 ± 0.005   0.31            CpG_2    229/151   0.07 (0.06--0.10)      0.07 (0.06--0.09)      1.00                
  cg12848864      48/48          0.051 ± 0.007                       0.048 ± 0.007   0.38            CpG_4    229/151   0.07 (0.06--0.10)      0.07 (0.06--0.09)      1.00                
  cg03165700      48/48          0.047 ± 0.007                       0.044 ± 0.005   0.16            CpG_5    229/151   0.07 (0.06--0.10)      0.07 (0.06--0.09)      1.00                
  cg15504467      48/48          0.027 ± 0.003                       0.026 ± 0.004   0.36            CpG_6    229/151   0.00 (0.00--0.00)      0.00 (0.00--0.00)      1.00                
  cg05033322      48/48          0.028 ± 0.004                       0.027 ± 0.003   0.82            CpG_7    229/151   0.05 (0.03--0.06)      0.04 (0.03--0.06)      1.00                
  cg16693212      48/48          0.033 ± 0.004                       0.031 ± 0.004   0.29            CpG_8    229/151   0.05 (0.03--0.06)      0.04 (0.03--0.06)      1.00                
  cg15370815      48/48          0.074 ± 0.007                       0.072 ± 0.007   0.60            CpG_10   229/151   0.11 (0.10--0.13)      0.12 (0.10--0.13)      1.00                
  cg16788234      48/48          0.052 ± 0.008                       0.051 ± 0.007   0.82            CpG_11   229/151   0.11 (0.10--0.13)      0.12 (0.10--0.13)      1.00                
  cg24030675      48/48          0.013 ± 0.001                       0.013 ± 0.001   0.58            CpG_17   229/151   0.00 (0.00--0.04)      0.01 (0.00--0.04)      1.00                
  cg06053805      48/48          0.012 ± 0.001                       0.011 ± 0.003   0.14            CpG_18   229/151   0.13 (0.12--0.16)      0.14 (0.12--0.18)      0.22                
  cg06750635      48/48          0.012 ± 0.001                       0.011 ± 0.001   0.69            CpG_19   229/151   0.13 (0.12--0.16)      0.14 (0.12--0.18)      0.22                
  cg25400013      48/48          0.016 ± 0.002                       0.016 ± 0.001   0.94            CpG_21   229/151   0.02 (0.02--0.03)      0.02 (0.02--0.03)      1.00                
  cg20342375 \*   48/48          0.021 ± 0.003                       0.020 ± 0.002   0.085           CpG_9    229/151   ---                    ---                    ---                 
  cg22837512 \*   48/48          0.023 ± 0.003                       0.023 ± 0.002   0.99            CpG_15   229/151   ---                    ---                    ---                 
  cg18391757 \*   48/48          0.025 ± 0.004                       0.025 ± 0.004   0.72            CpG_22   229/151   ---                    ---                    ---                 
  Mean            48/48          0.236 ± 0.002                       0.235 ± 0.002   0.79            Mean     229/151   0.047 (0.042--0.055)   0.048 (0.042--0.056)   1.00                

^a^ *p*-value was ajusted by age, batch, cell type and multiple test. ^b^ *p*-value for the difference between breast cancer patients and healthy controls was analyzed by Mann-Whitney *U* test and was adjusted by Bonferroni-Holm method, α = 0.00333 and α = 0.00227 for *RASSF1A* and *ATM* respectively. \* CpG sites were included in *RASSF1A* and *ATM* amplicons but were not investigated by Sequenom MassARRAY EpiTYPER assay in this study. Abbreviations: CTL, control; BC, breast cancer.
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###### 

Sample Information.

  Gene        Sample Type            Group           Number   Age (*y*, Mean ± SD)
  ----------- ---------------------- --------------- -------- ----------------------
  *RASSF1A*   Peripheral blood DNA   Sporadic BC     229      48.37 ± 7.08
  Controls    151                    43.76 ± 14.49            
  *ATM*       Peripheral blood DNA   Sporadic BC     229      48.37 ± 7.08
  Controls    151                    43.76 ± 14.49            
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###### 

Bisulfite-specific primers for the target amplicons.

  Target          Primer                                                     Sequence (5′-3′)
  --------------- ---------------------------------------------------------- -------------------------------------
  ***RASSF1A***   sense                                                      aggaagagagGTAATGGAAATTTGGGTGTAGGGAT
  antisense       cagtaatacgactcactatagggagaaggctCTAACAACCCAAAATAACAAAACCA   
  ***ATM***       sense                                                      aggaagagagAGGGAAAATTTTTGGTTTTAAAGGT
  antisense       cagtaatacgactcactatagggagaaggctCCATATCCACCAATAACCAAC       
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###### 

Sequences of the target amplicons.

  Amplicon        Sequence (5′-3′)
  --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***RASSF1A***   GCAATGGAAACCTGGGTGCAGGGACTGTGGGGCC[CG]{.ul}AAGG[CG]{.ul}GGGCTGGG[CGCG]{.ul}CTCT[CG]{.ul}CAGAGCCCCCCC[CG]{.ul}CCTTGCCCTTCCTTCCCTCCTT[CG]{.ul}TCCCCTCCTCACACCCCACCC[CG]{.ul}GA[CG]{.ul}GCCACAA[CG]{.ul}A[CG]{.ul}G[CG]{.ul}AC[CG]{.ul}CAAAGCACCA[CGCG]{.ul}GAGATACC[CG]{.ul}TGTTTCTGGAGGCCAGCTTTACTGTGCTAGAGGAAGAGGGTCCCCACATC[CG]{.ul}GCCCTGGCCCTCCTGGTC[CG]{.ul}GTTTGCTGAAGCAACACACTTGGCCTACCCACTGGGTGGGGCAGGAAGTCT[CG]{.ul}AGCCTTCACTTGGGGTGAGGAGGAGGGAGAT[CG]{.ul}GTCAGCAGCTTTAC[CG]{.ul}CC[CG]{.ul}CTCTGCTCTCCACTG[CG]{.ul}GAGACTGGGGCTC[CG]{.ul}GCAGAGGCTGGAC[CG]{.ul}TGATCTTGAGGTTCAGGGGTGCATTCTGGGTGGATTCCCTTGGCATGGGTGGT[CG]{.ul}GCCCTCAGCAACTGCAGCCCTCATTTGGCTCTGTCACCCTGGGCTGCCAG
  ***ATM***       AGGGAAAACCTTTGGCCTCAAAGGTCCTTCTGTCCAGCATAGC[CG]{.ul}GGTCCAATAACCCTCCATCC[CGCG]{.ul}TC[CGCG]{.ul}CTTACCCAATACAAGC[CG]{.ul}GGCTA[CG]{.ul}TC[CG]{.ul}AGGGTAACAACATGATCAAAACCACAGCAGGAACCACAATAAGGAACAAGACTCAGGTTAAAGCAAACACAG[CG]{.ul}ACAGCTCCTG[CG]{.ul}C[CG]{.ul}CATCTCCTGGTTCCAGTGG[CG]{.ul}GCACTGAACT[CGCG]{.ul}GCAATTTGTCC[CG]{.ul}CCTCTTT[CG]{.ul}CTTCA[CG]{.ul}GCAGCCAAT[CG]{.ul}CTTC[CG]{.ul}CCAGAGAAAGAAAGG[CG]{.ul}C[CG]{.ul}AAATGAAACC[CG]{.ul}CCTC[CG]{.ul}TT[CG]{.ul}CCTT[CG]{.ul}GAACTGT[CG]{.ul}TCACTTC[CG]{.ul}TCCTCAGACTTGGAGGGG[CG]{.ul}GGGATGAGGAGGG[CG]{.ul}GGGAGGA[CG]{.ul}A[CG]{.ul}AGGG[CG]{.ul}AAGAGGGTGGGTGAGAGCCC[CG]{.ul}GAGCC[CG]{.ul}AGC[CG]{.ul}AAGGG[CG]{.ul}AGC[CG]{.ul}CAAA[CG]{.ul}CTAAGT[CG]{.ul}CTGGCCATTGGTGGACATGG
